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2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), the prototypic ligand for the aryl hydrocarbon receptor (AhR), promotes tumor
formation in some model systems. However, with regard to breast cancer, epidemiological and animal studies are
inconclusive as to whether exposure increases tumor incidence or may instead be protective. We have previously reported
that mice exposed to TCDD during pregnancy have impaired differentiation of mammary tissue, including decreased branching
and poor development of lobuloalveolar structures. Because normal pregnancy-induced mammary differentiation may protect
against subsequent neoplastic transformation, we hypothesized that TCDD-treated mice would be more susceptible to
chemical carcinogenesis after parturition. To test this, mice were treated with TCDD or vehicle during pregnancy. Four weeks
later, 7,12-dimethylbenz[a]anthracene (DMBA) was administered to induce mammary tumor formation. Contrary to our
hypothesis, TCDD-exposed parous mice showed a 4-week delay in tumor formation relative to controls, and they had a lower
tumor incidence throughout the 27-week time course. The same results were obtained in nulliparous mice given TCDD and
DMBA on the same schedule. We next addressed whether the delayed tumor incidence was a reflection of decreased tumor
initiation, by testing the formation of DMBA-DNA adducts and preneoplastic lesions, induction of cytochrome P450s, and cell
proliferation. None of these markers of tumor initiation differed between vehicle- and TCDD-treated animals. The expression of
CXCL12 and CXCR4 was also measured to address their possible role in tumorigenesis. Taken together, our results suggest
that AhR activation by TCDD slows the promotion of preneoplastic lesions to overt mammary tumors.
The aryl hydrocarbon receptor (AhR) is an orphan nuclear
receptor that belongs to the per-arnt-sim (PAS) family of
transcriptional regulators.1 For many years, this receptor has
been studied primarily because of its role in the toxic effects
of dioxin-like compounds, which are ubiquitous and long-
lived contaminants in the environment.2 Recently, however,
interest in further understanding this receptor has been bol-
stered by numerous reports indicating that the AhR plays a
role in normal development, carcinogenesis and cell cycle
regulation, and likely has endogenous ligands with important
biological functions.3–6 Because of such discoveries, the
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development of nontoxic analogs of known AhR ligands for
therapeutic use has begun to be explored.7–9
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is the best
characterized AhR ligand, and it affects many organ systems
and deregulates numerous cellular pathways.2,10 TCDD is also
classified as a Class 1 carcinogen by the International Agency
for Research on Cancer11 and is established as a promoter for
certain tumors including liver and skin.12,13 For breast cancer,
however, the relationship between exposure to AhR ligands and
cancer risk is unclear. There are conflicting reports as to
whether exposure to AhR ligands is associated with increased
incidence of mammary neoplasias, or if it may in fact protect
against breast cancer. Investigations of human populations
exposed to dioxin-like chemicals report mixed findings of
increased and decreased association with breast cancer risk,
whereas others fail to show any correlation at all.14–17
Collectively, studies conducted in rat models indicate that
susceptibility to mammary tumors likely correlates with the age
of the animal, and by extension the differentiation state of the
mammary gland, at the time of TCDD exposure. For example,
studies conducted by Safe and coworkers using mature adult
rats demonstrated that TCDD, and other AhR agonists, can
actually cause regression of existing chemical-induced
tumors.18–20 Similarly, Kociba et al.21 found reduced incidence
of spontaneous mammary tumors in a long-term feeding with
TCDD, despite increases in incidence of tumors at other loca-
tions. In contrast to the experiments wherein TCDD is adminis-
tered to adult rats, other studies addressing developmental expo-
sure to TCDD have demonstrated increased sensitivity to
mammary tumorigenesis. Specifically, Lamartiniere and co-
workers have shown that prenatal exposure to TCDD, which
alters normal development of the mammary gland, increased
the incidence of 7,12-dimethylbenz[a]anthracene (DMBA)-
induced mammary tumors later in life.22,23 Finally, during the
neonatal and weaning period, administration of AhR agonists
may also influence subsequent development of mammary
tumors, with somewhat conflicting results depending on the
timing of exposure and the mixture administered.24,25
One emerging paradigm to reconcile these seemingly con-
flicting results is that the ultimate susceptibility of mammary
tissue to carcinogenic insult is dependent upon the status of
the tissue at the time of AhR activation. More specifically,
one way by which AhR ligands such as TCDD influence
mammary tumorigenesis is interfering with normal timing of
development and differentiation of the gland, such as during
fetal development.26,27 In support of this idea, Lamartiniere
and coworkers have shown that developmental exposure to
TCDD significantly increases the relative number of terminal
end buds (TEB) compared with developed Type II lobules at
postnatal day 50.22 Because TEB are very susceptible to carci-
nogenic transformation, this hypothesis fits well with the
observed increase in sensitivity to DMBA-induced tumori-
genesis in rats exposed developmentally to TCDD.22,23
The differentiation of mammary tissue that occurs during
pregnancy represents another critical window during which
TCDD exposure causes profound suppression of normal de-
velopment. Specifically, we have shown that mice treated
with TCDD starting at the very beginning of pregnancy have
observable defects in branching as early as day 6, and
severely stunted development of lobuloalveolar structures
with concomitant suppression of milk production by the end
of pregnancy.28,29 Given that AhR activation impairs preg-
nancy-associated mammary gland development, we hypothe-
sized that these defects would influence susceptibility to
tumorigenesis postpartum. The rationale for this idea is that
pregnancy-induced changes in the mammary gland may pro-
vide protection against breast cancer later in life.30–32 Although
the specific alterations responsible for this protection are not
fully understood, this protective effect is thought to result
from permanent changes in the differentiation status or fate of
the mammary cells that are induced by pregnancy.30–32
The goal of the studies presented here was to determine
whether mice treated with TCDD during pregnancy demon-
strate increased susceptibility to a mammary carcinogen
administered after parturition. In other words, we considered
that our discovery that TCDD suppresses pregnancy-induced
mammary differentiation provides at least one mechanistic
explanation for the correlation between AhR-mediated per-
turbation of normal mammary differentiation and altered
incidence of breast cancer. Interestingly, our results showed
that AhR activation delayed tumorigenesis regardless of preg-
nancy status and despite the suppression of pregnancy-
induced glandular development. Further exploration into the
mechanism of the delay suggested that prior AhR activation
does not reduce carcinogen-induced DNA damage and the
initiation phase of carcinogenesis. Instead, we postulate that
the fate of the mammary epithelial cells is persistently altered
by AhR activation to slow the proliferation and promotion of
initiated cells.
Material and Methods
Animals
Female CB6F1 mice were obtained from NCI Charles River.
Both parental strains (BALB/c and C57Bl/6) express the high
affinity AhRb allele that confers sensitivity to TCDD.33 Ani-
mals were given food and water ad libitum and were main-
tained on a 12:12-hr light cycle. For experiments conducted
in pregnant animals, female mice (age 6–7 weeks) were
housed with males and checked daily for presence of vaginal
plugs. Day 0 of pregnancy was designated as the day the vag-
inal plug was found. All treatment was in accordance with
protocols approved by the Washington State University Insti-
tutional Care and Use Committee.
Chemicals and animal exposures
TCDD was dissolved in anisole and diluted in peanut oil to a
concentration for dosing at 10 ll/g body weight. Mice were
administered TCDD in 3 weekly doses of 10 lg/kg (on day 0
and 7) and 5 lg/kg (on day 14). Preliminary dose-response
studies indicated that 10 lg/kg TCDD on days 0 and 7 was
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necessary for substantial suppression of pregnancy-induced
gland differentiation in this strain. The dose given on day 14
was decreased to speed clearance of TCDD from the body af-
ter parturition. Mice were treated every 7 days to maintain a
relatively constant body burden of TCDD throughout preg-
nancy; the half-life of TCDD in mice is 11 days.34 Nullipar-
ous mice were treated under the same TCDD paradigm as
pregnant mice to serve as controls for the effect of preg-
nancy. Nulliparous mice were also used for some of the
mechanistic studies, due to the fact that pretreatment with
TCDD was determined to affect tumor formation equiva-
lently in parous and nulliparous mice, and because it is logis-
tically easier to maintain and treat nulliparous mice for tissue
collection. Vehicle control for the TCDD treatments con-
sisted of peanut oil containing an equivalent concentration of
anisole. DMBA (Sigma, St. Louis, MO) was dissolved in ses-
ame oil under gentle heat to a final concentration of 5 mg/ml
(for administering 1 mg in 200 ll).35 The solution was stored
at 4C and kept protected from light at all times. Sesame oil
was given as the vehicle control for the DMBA treatments.
Both TCDD and DMBA, and their vehicle controls, were
administered by gavage.
Tumor study
Experimental design overview. A graphic of the experimental
design is shown in Figure 1. Female mice CB6F1 mice (age
6–7 weeks) were housed with males and checked daily for
presence of vaginal plugs. Pregnant mice (n ¼ 32 per treat-
ment group) were treated with 10 lg/kg of TCDD, or peanut
oil vehicle, on days 0 and 7 of pregnancy, and with 5 lg/kg
on day 14. Pups were removed at birth to eliminate lactation
as a potential confounding factor (dams treated with these
doses of TCDD do not lactate and their pups would not sur-
vive28). The dams received no further treatment for 4 weeks
after the final TCDD treatment, which is equivalent to 3
weeks after parturition, to decrease the residual body burden
of TCDD and to permit the glands to regress. Following the
no exposure period, mice were treated with 1 mg DMBA per
week for 6 weeks.36 Nulliparous age-matched animals were
treated with the same doses of TCDD (n ¼ 20) or its vehicle
(n ¼ 22) and with DMBA on the same schedule as the parous
mice. Control groups of vehicle- and TCDD-treated parous
mice (n ¼ 20 per treatment group) were not given DMBA,
but instead were administered sesame oil vehicle. These non-
DMBA control animals never developed palpable tumors.
Tumor assessment. Mammary tumor formation was moni-
tored by physical palpation twice weekly, beginning 5 weeks
after the final administration of DMBA. The location of the
tumors was recorded. Once a tumor had enough 3-dimen-
sional structure to measure, the size was monitored weekly
using a vernier caliper. Two perpendicular diameters, termed
length (L) and width (W), were determined, with length
defined as the larger of the two measurements. Volume was
calculated using the formula 4/3  p  (L/2)  (W/2)2.37
The multiplicity of tumors was determined as follows: (the
total number tumors per group)/(number of mice with
tumors in that group).
Termination. Mice were euthanized by carbon dioxide over-
dose when a tumor length reached 25 mm, or if at any time
the animal appeared uncomfortable or moribund. The tumor
study was terminated at 27 weeks after the final DMBA
administration. At that time, greater than 90% of the mice in
each DMBA group had either developed palpable tumors or
had died of other causes. DMBA is a multisite carcinogen,
and some of the mice developed other malignancies (often
Figure 1. Tumor study design and animal treatment. Six groups of CB6F1 mice (age 6–7 weeks at the start of the experiment) were
included in this study. Pregnant mice were treated with vehicle (n ¼ 32) or TCDD (n ¼ 32) at 3 time points during pregnancy, followed by
6 weekly doses of DMBA beginning 4 weeks after the final TCDD treatment (equal to 3 weeks after parturition). Nulliparous age-matched
mice were treated with vehicle (n ¼ 22) or TCDD (n ¼ 20) and DMBA on the same schedule as the pregnant mice. Finally, vehicle- and
TCDD-treated control groups that did not receive DMBA were also included. For these ‘‘no DMBA’’ controls, pregnant mice were treated
with vehicle (n ¼ 20) or TCDD (n ¼ 20) during pregnancy, then given sesame oil (the vehicle control for DMBA) beginning 3 weeks
after parturition. No tumors developed in the mice that did not receive DMBA. See Methods for additional details about the TCDD
and DMBA treatments.
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thymoma, also ovarian, lung, etc.) that contributed to mor-
bidity and mortality.
Evaluation of preneoplastic lesions. Preneoplastic lesions,
including hyperplastic alveolar nodules (HAN), ductal carci-
noma in situ (DCIS), and ductal hyperplasia (DH) in the
mammary whole mounts, were quantified.38,39 Additionally,
nonpreneoplastic lesions in the gland were quantified, includ-
ing cystic nodules (CN), fine duct hyperplasias (FDH), dense
nodules (DN), and mammary tumors. CN were defined as
focal areas of dilated alveoli. DN were small highly stained
areas comprised of epithelial and stromal cells surrounded by
dense connective tissue and with a very low-mitotic index.
MT were microscopic foci of epithelial cells that proliferated
into the surrounding stroma. Samples of all types of lesions
were verified by histological sections. Lesions were identified
in a subset of mice (n ¼ 1119 per group) that were sacri-
ficed within a consistent window of time relative to DMBA
administration (22 weeks after final DMBA treatment).
Whole mounts
Mammary whole mounts were prepared as described previ-
ously.28 Briefly, the fourth and fifth mammary glands were
mounted onto a glass slide under weight, and fixed in Car-
noy’s fixative. Fixed glands were transferred to 70% ethanol,
rehydrated, and stained with carmine alum. Glands were
then dehydrated, cleared with xylenes, and mounted using
Permount (Fisher Scientific, Pittsburgh, PA). Whole mounts
were examined and given a development score based on a
four-point scale. The development scores considered epithe-
lial branching, development of lobuloalveolar units, and the
size of the structures (1 ¼ poor development, 4 ¼ excellent
development). Photographs were taken at 3.1 using a
Jenoptik ProgRes C12plus digital camera attached to a Wild
Dissecting Microscope.
Western blotting
The levels of cytochrome P450s (Cyps) 1a1 and 1b1 and of
AhR were assessed in protein extracts from mammary gland
and/or liver. Tissues were homogenized in RIPA buffer and
protease inhibitors using a Tissue Tearor (Biospec Products).
The proteins in the supernatant were quantified and boiled
in SDS-PAGE sample buffer. Protein (30 lg) was separated
on 8% acrylamide gels, and transferred to PVDF membranes.
Primary antibodies for Cyp1a1, Cyp1b1, and actin were pur-
chased from Santa Cruz Biotech (Santa Cruz, CA), and the
primary antibody for AhR was purchased from BIOMOL
International (now Enzo Life Sciences, Plymouth Meeting,
PA). Secondary antibodies included IRDyeTM 700DX Conju-
gated anti-goat IgG (Li-Cor, Lincoln, NE) and HRP-conju-
gated anti-rabbit antibody (DakoCytomation, Glostrup, Den-
mark). Bands were visualized using the Li-Cor OdysseyTM
Infrared Imaging System (for IRDye reagents), or by exposure
to X-ray film following incubation with chemiluminescent
ECL reagents (for HRP-conjugated reagents). The intensity of
the bands was evaluated using the Li-Cor software or from
scans of X-ray films using Quantity One (BioRad, Hercules,
CA), as appropriate for each secondary antibody conjugate.
DMBA-DNA adduct assay
Genomic DNA from homogenized mammary glands was iso-
lated by a standard phenol–chloroform extraction method.40
DNA adducts were determined for each DNA sample using
the nuclease P1 enrichment version of the 32P-postlabeling
method as described previously.41,42 Briefly, DNA samples (4
lg) were digested with micrococcal nuclease (120 mU) and
calf spleen phosphodiesterase (40 mU), enriched and labeled
as reported. Chromatographic conditions for thin-layer chro-
matography (TLC) on polyethyleneimine-cellulose (PEI-cellu-
lose) (10 cm  20 cm; Macherey-Nagel, Du¨ren, Germany)
were: D1, 1.0 M sodium phosphate, pH 6; D3, 3.5 M lith-
ium-formate, 8.5 M urea, pH 3.5; D4, 0.8 M lithium chloride,
0.5 M Tris-HCl, 8.5 M urea, pH 8. After chromatography,
TLC sheets were scanned using a Packard Instant Imager
(Dowers Grove, IL) and DNA adduct levels [(RAL) relative
adduct labeling] were calculated from adduct cpm, the spe-
cific activity of [c-32P]ATP and the amount of DNA (pmol
of DNA-P) used. Results were expressed as DNA adducts/108
nucleotides.
Cell proliferation analysis
The incorporation of bromodeoxyuridine (BrdU) was used to
measure the proliferation status of mammary epithelial cells.
An intraperitoneal injection of BrdU (50 mg/kg, Sigma-
Aldrich, St. Louis, MO) was given 1 day before sacrifice. Ab-
dominal-inguinal mammary glands were formalin-fixed, par-
affin-embedded, and sliced for immunohistochemical (IHC)
analysis of BrdU incorporation. A BrdU IHC System Kit
(Calbiochem, San Diego, CA) was used to stain the BrdU
positive cells according to the manufacturer’s instructions. To
count the BrdU positive epithelial cells in each tissue slice, 10
images were generated for one slice of each gland using
QCapture Pro51 software (Qimaging, Surrey, BC, Canada)
and a Nikon microscope at magnification 400.
Real-time PCR
Quantitative real-time PCR (qRT-PCR) analyses were per-
formed to measure mRNA levels of the chemokine CXCL12
and its receptor CXCR4 in mammary tissue and tumors.
Actin was used as an endogenous control. Total RNA was
extracted from mammary glands homogenized in TRIzol rea-
gent (Invitrogen, Carlsbad, CA). Total RNA (1 lg) was
reverse-transcribed to single strand cDNA using High-
Capacity cDNA Reverse Transcription kit [Applied Biosys-
tems (ABI), Foster City, CA]. qRT-PCR reactions were per-
formed using the ABI Prism 7000 Sequence Detection Sys-
tem. TaqMan reagents and gene expression assays were from
ABI. A 25 ll reaction mixture containing 5 ll of cDNA tem-
plate, 12.5 ll TaqMan Universal PCR master mix, and 1.25
ll primer probe mixture was amplified using the following
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thermal cycler parameters: denaturation at 95C for 10 min,
then 40 cycles of the amplification step (denaturation at 95C
for 15 sec and annealing/extension at 60C for 1 min). Raw
CT (cycle threshold) values were obtained from the ABI7000
software, and used to compare the mRNA levels between the
vehicle- and TCDD-treated groups. The fold-change between
the treatment groups was calculated by first determining the
DCT value [DCT ¼ CT (target RNA)  CT (endogenous
control)] for each sample. The unlogged DCT (¼ 2DCT) was
then determined for each vehicle-treated animal, then nor-
malized to 1 using the average unlogged DCT of all samples
in that group. The relative fold-change for each TCDD-
treated animal was calculated by comparison with the average
of the vehicle-treated group. The unlogged DCT (¼ 2DCT)
for each animal was used for statistical analysis.
Statistics
Tumor incidence was analyzed by Fisher’s exact test and by
ANOVA, using Tukey’s test for pairwise comparisons. Other
comparisons were made using Student’s t-test. A p-value of
0.05 was considered significant. Statistical analyses were
performed using Prism (GraphPad Software, La Jolla, CA) or
Minitab (Minitab, State College, PA).
Results
Part 1: Effect of AhR activation on mammary gland
differentiation and tumor incidence
AhR activation suppresses pregnancy-induced differentiation
of mammary glands in CB6F1 mice. Previous studies con-
ducted in C57Bl/6 mice have demonstrated that AhR activa-
tion during pregnancy suppresses normal branching and
lobuloalveolar development in the mammary gland. The cen-
tral hypothesis for this study was that this suppressed differ-
entiation would result in increased susceptibility to mammary
tumorigenesis postpartum. Because C57Bl/6 mice are less sus-
ceptible to chemical-induced carcinogenesis than the Balb/c
strain,43 CB6F1 mice (Balb/c  C57Bl/6) were used for these
tumorigenesis studies. Therefore, the first objective was to
demonstrate the suppressive effect of TCDD on pregnancy-
induced gland differentiation in this particular mouse strain.
Impregnated mice were treated with 10 lg/kg TCDD on
days 0 and 7 of pregnancy, and with 5 lg/kg on day 14.
Mammary whole mounts were made from glands taken on
day 17 of pregnancy. As shown in Figure 2, AhR activation
decreased the normal branching that occurs during preg-
nancy and resulted in poor development of lobuloalveolar
structures. Development scores quantifying the amount of
differentiation in glands showed that the suppression caused
by TCDD treatment was statistically significant (Fig. 2c). The
effects presented in Figure 2 are similar to those reported
previously in TCDD-treated C57Bl/6 mice.28,29
Prior AhR activation decreases susceptibility to DMBA-
induced mammary tumorigenesis. Evidence in both humans
and rodents suggests that pregnancy may cause changes in
mammary cells that reduce the probability of developing
mammary tumors later in life.32,44–46 Because TCDD sup-
presses differentiation of the mammary gland when given to
mice during pregnancy, we tested whether these mice would
be more susceptible to DMBA-induced tumor formation later
on. To accomplish this, mice were treated with TCDD or ve-
hicle control during pregnancy, pups were removed at birth
and the dams remained untreated for 3 weeks post-partum.
DMBA was administered once a week for 6 weeks, and
Figure 2. Mammary gland differentiation that occurs during
pregnancy is disrupted by AhR activation. Impregnated CB6F1 mice
were treated with vehicle (a; n ¼ 7) or TCDD (b; n ¼ 5) at three
times during pregnancy (10 lg/kg on day 0 and day 7, and 5 lg/kg
on day 14). Whole mounts of the abdominal mammary glands were
made on day 17 of pregnancy, fixed, and stained with carmine alum.
(c) Glands were given scores that considered epithelial branching,
development of lobuloalveolar units, and the size of the structures.
Bars indicate the mean score for each treatment group (6SEM).
*p  0.05. Representative photographs of glands from vehicle-treated
(a, developmental score ¼ 4) and TCDD-treated (b, developmental
score 1.5) mice were taken at 3.1. [Color figure can be viewed in
the online issue, which is available at wileyonlinelibrary.com.]
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palpable tumors were evaluated over time. Interestingly, we
found that mice treated with TCDD during pregnancy had a
decreased tumor incidence relative to the vehicle-treated
parous animals at all times examined (Fig. 3a). Specifically,
the number of tumor-positive mice at a given time point was
decreased by an average of 17% in the TCDD-treated group
compared with the vehicle-treated group (range 9–22% lower,
depending on the week). The difference between the two
groups was highly significant (p < 0.0001). Furthermore, the
average week of tumor onset (relative to the final DMBA
treatment) was delayed by nearly 4 weeks in the TCDD-
treated animals (Fig. 3e, parous mice, p < 0.05).
The same beneficial effect of prior AhR activation was
observed in nulliparous mice treated with DMBA (Fig. 3b,
p < 0.0001). Specifically, the number of tumor-positive mice
at a given time point was decreased by an average of 18% in
the TCDD-treated group compared with the vehicle-treated
group (range 7–30% lower, depending on the week). The
average time of tumor onset was also delayed by over 3
weeks in mice with prior TCDD exposure (Fig. 3e, nullipar-
ous mice, p ¼ 0.065).
Parity status alone does not alter tumor incidence. A sepa-
rate but important consideration in these studies was the
effect of parity status on tumor incidence. Pregnancy is
hypothesized to protect against tumor development in rats
and humans, and therefore, nulliparous mice were included
in the study to serve as controls for the parous animals.
However, our results showed that a single pregnancy did not
protect against tumor development, because tumor formation
in nulliparous mice was essentially the same as for the parous
animals. In other words, there were no statistically significant
differences in the tumor incidence curves between the vehi-
cle-treated parous mice and the vehicle-treated nulliparous
animals (Fig. 3c; p ¼ 0.30). Neither did we observe differen-
ces between the TCDD-treated parous animals and the
TCDD-treated nulliparous mice (Fig. 3d; p ¼ 0.18).
Tumor size and multiplicity are not significantly altered by
prior AhR activation. We next determined whether growth of
the mammary tumors was affected by prior exposure to
TCDD. It is important to emphasize that we intentionally
addressed the growth rate of tumors once they had formed.
That is, given that there was an overall delay in tumor for-
mation in the TCDD-treated mice, the number and size of
tumors in TCDD groups were smaller at a given week fol-
lowing DMBA exposure. Therefore, the growth of each tu-
mor was monitored relative to the time of initial onset in
that animal.
Tumor growth was assessed in three ways. First, we calcu-
lated the number of days between the time each tumor was
first detectable by palpation and when it grew large enough
to measure with calipers. As shown in Figure 3f, prior TCDD
exposure caused a statistically significant retardation of tumor
growth in the nulliparous mice, but not in parous animals.
This result is suggestive that prior AhR activation slows tu-
mor growth in addition to the timing of tumor onset, and
that the protective effect is more pronounced in nulliparous
animals. However, for the other two methods used to evalu-
ate tumor growth, we did not observe a difference based on
parity or TCDD pretreatment. Specifically, when we deter-
mined the volume of each tumor on days 7, 14, and 21 after
the tumor was first large enough to measure, neither prior
exposure to TCDD nor parity status affected tumor volume
at any time point (data not shown). Likewise, the number of
tumors that formed in each affected animal was not signifi-
cantly affected by either TCDD treatment or parity (tumor
multiplicity: vehicle-parous ¼ 1.13, TCDD-parous ¼ 1.37; ve-
hicle-nulliparous ¼ 1.53, TCDD-nulliparous ¼ 1.45).
Part 2: Effect of AhR activation on tumor initiation
Chemical carcinogenesis is considered a multistep process,
consisting of initiation, promotion, and progression. In the
next series of experiments, we addressed the hypothesis that
prior activation of the AhR specifically alters tumor initiation.
Initiation parameters examined included P450 induction and
DNA damage, carcinogen-susceptible proliferating epithelial
cells, and formation of preneoplastic lesions.
Persistent AhR activation and Cytochrome P450 induction is
unlikely at the time of carcinogen administration. In the ex-
perimental design for the tumor study, administration of the
carcinogen (DMBA) began 4 weeks after the final treatment
with TCDD. The intent of this delay was in part to allow
time for the TCDD to be cleared and reduce/eliminate the
influence of persistent AhR activation at the time the tumors
were forming. In other words, our intent was to test whether
the fate of the mammary epithelial cells was changed by prior
AhR activation, not to examine the effect of concurrent AhR
activation on a carcinogenic insult. However, it remained
possible that the AhR was still activated 4 weeks after TCDD
treatment, such that persistent induction of P450 enzymes
could alter the biotransformation of the carcinogen DMBA.
To address AhR activation status at the time of DMBA
administration, the levels of Cyp1a1 and Cyp1b1 proteins
were measured 4 weeks after the final treatment with TCDD,
using a cohort of mice separate from the tumor study. For
comparison, the induction of these enzymes was also deter-
mined 3 days after the final treatment with TCDD. As
expected, Cyp1a1 and Cyp1b1 were highly induced in both
the mammary gland and liver 3 days following TCDD treat-
ment (Fig. 4, left panels). However, in the mammary gland,
these enzymes were completely absent by 4 weeks after treat-
ment (Fig. 4a, right panels). Similar results were observed in
the liver samples, where Cyp induction was markedly
reduced, although still detectable and statistically different (p
< 0.05), by 4 weeks post-exposure (Fig. 4b, right panels).
These results strongly support the conclusion that persistent
AhR activation, particularly in the mammary gland itself, is
not responsible for the delay in tumor formation. Further-
more, the absence of persistent induction of Cyp enzymes
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Figure 3. Prior treatment with TCDD delays tumor formation in DMBA-treated parous and nulliparous mice. The development of mammary
tumors was monitored by physical palpation beginning 5 weeks after the final treatment with DMBA and continued for 27 weeks. (a)
Incidence of mammary tumors in DMBA-treated parous mice (triangles) that had been treated with vehicle (open triangles, n ¼ 32) or TCDD
(filled triangles, n ¼ 32) during pregnancy. The difference between the two groups was highly significant (p < 0.0001 as analyzed by
ANOVA using a Tukey’s test for pairwise comparisons). No tumors formed in parous control mice that were not given DMBA (vehicle group
¼ open diamonds, n ¼ 20; TCDD group ¼ X symbol, n ¼ 20). (b) Tumor incidence in DMBA-treated nulliparous mice (circles) that had
been treated with vehicle (open circles, n ¼ 22) or TCDD (filled circles, n ¼ 20) and DMBA on the same schedule as the parous mice. The
difference between the two groups was highly significant (p < 0.0001). (c and d) The same experimental groups shown in (a) and (b) were
regraphed to demonstrate the observed lack of effect of pregnancy on subsequent tumor incidence. The incidence of mammary tumors in
DMBA-treated parous (triangles) and nulliparous mice (circles) is shown both for mice pretreated with vehicle control (c) or with TCDD (d).
Statistical comparisons showed no difference between the parous and nulliparous groups (p ¼ 0.30 for c; and p ¼ 0.18 for d). (e) Average
time of tumor onset (6SEM) relative to the final DMBA treatment. (f) Growth rate was assessed by determining the number of days
between the time each tumor was first detected by palpation until it grew large enough to physically measure with vernier calipers.
*p  0.05; #p ¼ 0.065.
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suggests that differences in DMBA metabolism are unlikely
to account for the delay in tumor formation in the mice pre-
treated with TCDD.
Given that TCDD treatment is known to cause rapid
degradation of the AhR, which could likewise affect the
response to DMBA, we also examined the level of AhR pro-
tein in the mammary glands. Consistent with other reports
showing diminished AhR expression in cultured cell lines,
mammary gland, and other tissues,47–50 we found that AhR
levels in the mammary gland were significantly lower in
TCDD-treated mice when assessed 3 days following treat-
ment (Supporting Information Fig. 1). However, AhR levels
had recovered within the 4 weeks following the final TCDD
exposure, and there was no persistent difference in receptor
levels between the treatment groups at the time DMBA was
administered.
Influence of TCDD on DMBA-DNA adduct levels. The initiation
phase of chemical carcinogenesis begins with damage to the
DNA bases. For DMBA, metabolites of the chemical form
covalent adducts with DNA that can result in DNA mis-
match and mutation. To directly test whether prior exposure
to TCDD alters the formation of these lesions, the amount of
DMBA-DNA adducts in the mammary glands was investi-
gated by 32P-postlabeling analysis. Representative TLC auto-
radiographs are shown in Figure 5a. The adduct pattern
Figure 4. Cytochrome P450 induction is transient and returns to baseline by 4 weeks following TCDD treatment. Cyp1a1 (56 kDa) and
Cyp1b1 (57 kDa) were assessed in protein extracts from (a) mammary gland and (b) liver using Western blotting. Mice were treated with 3
weekly doses of vehicle or TCDD, as described in the Methods. Tissues were collected at two time points, including 3 days after, and 4
weeks after the final vehicle or TCDD treatment. The positive (þ) control for Cyp1a1 is liver extract from a TCDD-treated mouse, and for
Cyp1b1 is protein from cultured mammary epithelial cells (SCp2 cells) treated with 109 M TCDD for 5 days. Actin (43 kDa) was used as a
loading control. Bar graphs in (b) illustrate the magnitude of the difference in Cyp1a1 induction present at 3 days vs. 4 weeks following
TCDD exposure. Similar results were obtained for Cyp1b1. Tissues from pregnant mice were used in the 3 day time point, and nulliparous
mice were the source of tissues taken at 4 weeks. Parity status did not substantially affect baseline Cyp expression in the liver of vehicle-
treated animals when proteins were compared on the same blots (14% difference, not shown). *p  0.05.
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observed after oral administration of DMBA (in the presence
or absence of TCDD) was similar to that found in mouse
skin epidermis after topical application.41 It consisted of three
major adduct spots, which have been shown to represent
DMBA-DNA adducts formed by bay-region diol epoxides.
No DNA adducts were detected in non-DMBA control tis-
sues (data not shown). Total DMBA-DNA adduct levels are
illustrated in Figure 5b. The level of DMBA-DNA adducts
increased in response to the number of DMBA treatments
the animals received, at around 120 and 350 adducts per 108
nucleotides after one and six DMBA doses, respectively.
However, prior treatment with TCDD did not change the
damage to the DNA bases (adducts) caused by DMBA.
Proliferation status of mammary epithelial cells at the time of
carcinogen exposure. Mammary epithelial cells that are rap-
idly proliferating may be more susceptible to damage by car-
cinogens, as evidenced by the correlation between mammary
tumor incidence and number of proliferating cells in the
ducts and end buds.22,31,45 To test whether prior exposure to
TCDD reduced the number of proliferating mammary epi-
thelial cells (i.e., those cells possibly most susceptible to DNA
damage and mutation), BrdU incorporation was examined by
immunohistochemistry. Mice that had been treated with 3
weekly doses of vehicle or TCDD were injected with a single
dose of BrdU 4 weeks after their final treatment. Proliferating
cells were quantified by counting the number of cells that
stained positively for BrdU (Fig. 5c). The analysis revealed
that prior AhR activation did not diminish the number of
proliferating mammary epithelial cells 4 weeks later (Fig. 5d,
left columns, ‘‘baseline’’), which was the time at which the
DMBA was administered.
In separate groups of pretreated animals, a single dose of
DMBA was given (Fig. 5d, right columns, ‘‘DMBA’’). The
Figure 5. Prior activation of the AhR does not change the level of DMBA-DNA adducts in the gland or the proliferative status of mammary
epithelial cells. Nulliparous mice were treated with 3 weekly doses of vehicle or TCDD, as described in the Methods. (a and b) Four weeks
after the final vehicle or TCDD treatment, the carcinogen DMBA was administered to initiate tumor formation. Mice were sacrificed 24 hr
after receiving either one dose of DMBA, or after receiving 6 weekly doses of DMBA (n ¼ 6 mice per treatment group at each time point).
The number of DNA adducts in DNA extracted from the mammary glands was determined by 32P-postlabeling. (a) The patterns of DMBA-
DNA adducts are shown in representative TLC autoradiographs. Arrows indicate the three major adduct spots, which represent adducts
formed by DMBA bay-region diol epoxides. (b) Levels of adducts (RAL ¼ relative adduct labeling) in the vehicle- and TCDD-pretreated mice
that were subsequently given one or six doses of DMBA. (c and d) Four weeks after the final vehicle or TCDD treatment, the proliferating
mammary epithelial cells were labeled by injecting the animals with BrdU (‘‘Baseline’’). Separate groups of vehicle- and TCDD-exposed
animals were also administered a single dose of DMBA and sacrificed 6 days afterward (‘‘DMBA’’) (n ¼ 7 mice for each treatment group).
BrdU positive cells in mammary gland slices were detected by immunohistochemistry. (c) Examples of tissue sections showing the BrdU
stained cells (arrows) from vehicle- and TCDD-pretreated mice following DMBA exposure. Photographs were taken at 400. ‘‘D’’ indicates a
duct, ‘‘Ad’’ indicates adipocytes. (d) Quantification of the proliferating cells was conducted by counting the total number of BrdU stained
cells in 10 separate images from each gland. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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goal was to determine if prior AhR activation dampens the
proliferative response of the mammary epithelial cells result-
ing from DNA damage. As expected, the DMBA treatment
itself increased the number of proliferating cells relative to
cells from mice not given DMBA (baseline); however, there
was no effect of prior treatment with TCDD. Taken together,
these results show that TCDD does not cause persistent sup-
pression in the baseline proliferative status of mammary epi-
thelial cells, nor in their initial proliferative response to DNA
damage.
Evaluation of preneoplastic and other microscopic lesions. In
addition to macroscopic measurable tumors, DMBA and
other carcinogens induce the formation of other lesions in
the mammary gland, some of which are preneoplasias. To
ascertain whether prior activation of the AhR influences
formation of these microscopic lesions, six types of lesions
were evaluated in mammary glands from mice in the tu-
mor study. Specifically, these lesions included two preneo-
plastic lesions (HAN and DCIS/DH) and four others (CN,
FDH, DN, and MT). Table 1 shows the average number of
each type of lesion found in each animal, the percentage of
animals in each group with that lesion, and the multiplic-
ity of each lesion type. Overall, there were no consistent
differences in the incidence of these lesions between the
different treatment groups. These results further support
the conclusion that tumor initiation is not diminished by
prior activation of the AhR, because the number of pre-
neoplastic and other lesions in the TCDD-treated mice is
similar, and in some cases even slightly higher, than in ve-
hicle control mice.
Part 3: Effect of TCDD treatment on CXCL12
and CXCR4 in vivo
In a recent publication by Hsu et al.,51 the authors reported
that TCDD treatment of MCF-7 cells reduced the expression
of the chemokine CXCL12 and its receptor CXCR4. This dis-
covery may be significant because these two factors have
been implicated in breast cancer metastasis, and a reduction
in their expression was postulated to play a role in the pro-
tective role of AhR activation in breast cancer.
To address the potential for changes in CXCL12 and
CXCR4 to contribute to the delay in tumor growth in the
DMBA model, as well as to further characterize the expres-
sion of these factors in vivo, we determined their mRNA lev-
els using qRT-PCR. Mammary glands were collected from
mice treated with 3 weekly doses of vehicle or TCDD. In one
group of mice, CXCL12 and CXCR4 levels were examined 3
Table 1. Incidence of preneoplastic and other mammary lesions
Average number of each lesion per animal1
PNL Non-PNL
Group DCIS/DH HAN All PNL2 MT FDH DN CN All lesions (average number per animal)
Vehicle-parous 1.0 0.4 1.4 1.0 0.2 2.2 4.0 8.8
TCDD-parous 1.8 1.0 2.9 0.9 0.1 1.5 11.4 16.7
Vehicle-nulliparous 2.4 0.7 3.1 1.0 0.6 0.8 4.7 11.9
TCDD-nulliparous 1.2 1.9 3.1 1.1 0.2 1.1 4.5 9.9
Group
Percentage of animals per group with each lesion type
PNL Non-PNL
DCIS/DH HAN All PNL2 MT FDH DN CN
Vehicle-parous 45 36 54.5 55 18 64 73
TCDD-parous 63 37 73.7 47 11 58 100
Vehicle-nulliparous 64 36 54.5 55 36 55 82
TCDD-nulliparous 36 45 54.5 18 9 55 91
Group
Multiplicity3 of each lesion type
PNL Non-PNL
DCIS/DH HAN All PNL2 MT FDH DN CN
Vehicle-parous 2.2 1.0 2.5 1.9 1.0 3.5 5.5
TCDD-parous 2.9 2.8 3.9 1.8 1.2 2.6 11.4
Vehicle-nulliparous 3.8 1.8 5.6 1.9 1.6 1.6 5.8
TCDD-nulliparous 3.3 4.1 5.6 6.0 2.0 1.9 5.0
Abbreviations: DCIS: ductal carcinoma in situ; DH: ductal hyperplasia; HAN: hyperplastic alveolar nodule; PNL: preneoplastic lesion; MT: mammary
tumor; FDH: fine duct hyperplasias; DN: dense nodules; CN: cystic nodules.
1Sample size: vehicle-parous (n ¼ 11), TCDD-parous (n ¼ 19), vehicle-non-parous (n ¼ 11), TCDD-non-parous (n ¼ 11). 2DCIS, DH, and HAN are
considered preneoplastic lesions. 3Multiplicity ¼ (number of lesions per group)/(number of animals with that lesion per group).
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days after the final treatment with vehicle or TCDD. At this
time point, both CXCL12 and CXCR4 levels were signifi-
cantly increased in the TCDD-treated animals, by twofold
and 3.5-fold, respectively (Fig. 6a). However, when we exam-
ined message levels of CXCL12 and CXCR4 after 4 weeks,
the TCDD-mediated increase did not persist (Fig. 6b). More-
over, the levels of the mRNAs in the DMBA-induced mam-
mary tumors themselves were not found to differ between
the vehicle- and TCDD-treated groups (Fig. 6c). There was
suggestive evidence for a decrease in CXCR4 expression in
tumors from TCDD-treated mice; however, the difference
was not technically statistically significant.
Discussion
Breast cancer is among the leading killers of women world-
wide,52 and there is a clear need for developing novel thera-
peutic options and preventative measures. One strategy that
has been proposed for treating breast cancer is the use of
selective AhR modulators (SAhRMs). The use of such com-
pounds is based on the fact that AhR is expressed in mam-
mary cells and that AhR activation antagonizes estrogen re-
ceptor (ER) signaling and inhibits tumor growth.8,18–21
Additionally, new evidence suggests that SAhRMs may also
be effective in treating ER-negative tumors.9 The goal of the
current studies was to test whether AhR activation during
pregnancy affects susceptibility to a genotoxic mammary car-
cinogen administered weeks later. Interestingly, we found that
prior exposure to TCDD delayed tumor onset and reduced tu-
mor incidence in adult mice. Furthermore, this beneficial effect
of AhR activation occurred regardless of whether TCDD was
given during pregnancy or to nulliparous animals. These inter-
esting results provide additional support and insight for a pro-
tective role of AhR activation in mammary tumorigenesis.
In our studies, TCDD was administered 4 weeks before the
animals were given DMBA and 14 weeks had elapsed by the
time the first tumors formed. Therefore, it was important to con-
sider whether the beneficial effects resulted from persistent levels
of TCDD in the body or from persistent changes in the fate of
the mammary cells caused by previous AhR activation. To
address this, we examined the level of Cyp1a1 and Cyp1b1,
which are sensitive and commonly used biomarkers of AhR acti-
vation. Our results showed that Cyp expression in the mammary
gland itself had returned to background levels within the 4 weeks
following TCDD treatment. Given that only minute amounts of
TCDD are needed to induce Cyp1a1 and Cyp1b1,53 our results
do not support the idea that residual TCDD is directly affecting
tumor growth in our studies. Further support for this interpreta-
tion is provided by knowledge that the half-life of TCDD in
AhRb mice is 7–10 days,54,55 so the majority of the TCDD was
cleared before the growth phase of the tumors. Therefore, we
speculate that the protection afforded by prior AhR activation
results from a change in the fate of the mammary epithelial cells
that causes resistance to neoplastic transformation.
Although numerous studies have shown that AhR activa-
tion is protective against mammary carcinogenesis, the
Figure 6. Effect of TCDD on CXCL12 and CXCR4 expression. Parous
mice were treated with 3 weekly doses of vehicle or TCDD, as
described in the Methods. CXCL12 and CXCR4 expression were
analyzed by qRT-PCR using RNA isolated from mammary glands of
mice (n ¼ 5–6) sacrificed either 3 days (a), or 4 weeks (b), after
the final TCDD treatment. (c) mRNA isolated from mammary tumors
collected during the tumor study shown in Figure 3 (n ¼ 4) were
also analyzed. *p  0.05 and a fold-change of 2 relative to
vehicle [The decrease in CXCL12 expression in (b) is technically
statistically significant, but is substantially less than twofold. The
p value for the decrease in CXCR4 expression in (c) is 0.07.].
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precise mechanism of the protection remains unclear. We
began our investigation into the mechanism of delayed tumor
formation by examining the impact of prior AhR activation
on the initiation stage of carcinogenesis. Specifically, we
examined whether mice treated with TCDD 4 weeks prior
had (i) persistent induction of metabolic enzymes that bio-
transform DMBA, (ii) decreased numbers of DMBA-DNA
adducts, or (iii) diminished proliferation status of the mam-
mary epithelial cells at the time of carcinogen administration.
We also compared (iv) the levels of preneoplastic lesions in
the mammary glands of the TCDD- and vehicle-exposed ani-
mals. Each of these four markers relevant to tumor initiation
was equivalent in mice from both treatment groups, suggest-
ing that DNA damage and tumor initiation were not dimin-
ished by prior exposure to the AhR agonist. Taken together,
these data strongly suggest that prior AhR activation is not
altering tumor initiation in this model.
Instead, we speculate that prior AhR activation is interfer-
ing with the second stage of chemical carcinogenesis, tumor
promotion. This is supported by the findings that the level of
DMBA-DNA adducts and the incidence of preneoplastic
lesions was the same in the TCDD- and vehicle-treated mice,
yet the ultimate development of palpable tumors was sup-
pressed in TCDD-exposed animals. TCDD is known to influ-
ence tumor promotion in other models and is in fact estab-
lished as a tumor promoter in skin and liver.4,56,57 Although
these opposite effects in different tissues may at first appear
to be irreconcilable, it is plausible that they reflect cell- and
context-dependent differences in AhR-mediated effects on
cell cycle regulation and apoptosis. For example, AhR activa-
tion is known to influence cell proliferation and apoptosis in
many cell lines and tissues; however, the precise nature of
the effects (increased vs. decreased) vary depending on the
cell as well as by the treatment conditions.12,13,58–61 Thus, in
summary, because the TCDD-exposed mice in our studies
had a longer latency period and decreased mammary tumor
incidence at any given time point, it is more logical that
TCDD decreases promotion in this model. Furthermore
AhR-mediated suppression, or even reversal, of tumor pro-
motion is a reasonable explanation for the regression of pre-
existing mammary tumors reported previously.18–20
Although many studies in rodents show that AhR activa-
tion reduces mammary tumor growth, the complex relation-
ship between mammary tumorigenesis, constitutive expres-
sion and function of AhR in tumors, and activation of the
receptor by exogenous ligands is not fully elucidated. Studies
conducted by Sherr and coworkers demonstrate that AhR is
overexpressed in mammary glands and tumors from DMBA-
treated animals,62,63 and the receptor is also detected in
many breast cancer cell lines and human tumors.64–67 Endog-
enous expression and activation of AhR in mammary tumors
likely influences cell cycle regulation, and may promote tu-
mor growth by stimulating cell proliferation and inhibiting
apoptosis.68,69 On the other hand, AhR activation with
TCDD and SAhRMs typically inhibits breast cancer cell
growth in rodent models. This may be explained, at least for
ERþ cancer cells, by crosstalk between AhR and ER. For
example, exogenous AhR activation perturbs the expression or
function of numerous genes that influence proliferation of
breast cancer cells, including c-fos, TGF-b, TGF-a, and recep-
tors for progesterone, prolactin, and estrogen (reviewed in Ref.
70). Mechanisms for this antiestrogenic activity may include
competition between activated AhR and ER for shared cofac-
tors, binding of AhR to inhibitory response elements in pro-
moter regions of ER-inducible genes, or AhR-enhanced pro-
teosomal degradation of the ER.70–72 In future studies, we will
examine the status of AhR, hormone receptors, oncogenes,
and other modulators that influence growth of cancer cells.
This will require collecting lesions and tumors from vehicle
and TCDD pretreated mice systematically throughout the
course of tumor growth, and it is part of our ongoing investi-
gation into the underlying molecular pathways that are dis-
rupted by prior TCDD treatment to delay tumor onset.
A separate issue raised by these studies is unrelated to the
effect of AhR activation; specifically, the observation that
pregnancy alone did not protect against tumor formation. In
other words, the tumor incidence curve for the vehicle-
treated parous mice was not different from that of the vehi-
cle-treated nulliparous animals. Nor was there a difference in
tumor formation between the TCDD-parous and TCDD-nulli-
parous mice. This finding was somewhat surprising, because
pregnancy is hypothesized to protect against breast cancer in
humans and has been demonstrated in rat models.30–32 How-
ever, we are aware of only one report that has directly
addressed the protective effect of pregnancy in an analogous
chemical carcinogen-treated mouse model. Specifically, Medina
and Smith46 found that pregnancy plus lactation reduced the
incidence of DMBA-induced tumors by approximately three-
fold and lengthened the latency period by 10 weeks. Although
our current study did not show evidence of protection pro-
vided by pregnancy, differences in the experimental designs
may explain the different outcomes. Specifically, in the Medina
and Smith study the dams nursed their pups for 1 week,
whereas in this study, we removed the pups at birth. Given
that lactation is thought to further reduce the incidence of
mammary tumors above pregnancy alone,73 it is highly proba-
ble that this explains the differing outcomes in the two studies.
Our results also provide insight into understanding the
mechanism of protection against breast cancer afforded by
pregnancy. Specifically, we found that mammary cell differ-
entiation alone, at least differentiation that contributes to
branching and lobuloalveolar development, is not likely a
causal factor in parity-induced protection against tumor for-
mation. In this model, AhR activation during pregnancy dra-
matically suppressed branching, lobuloalveolar development,
and milk production (Fig. 2 and Refs. 28 and 29). However,
suppressed glandular development did not correlate with
increased risk of developing mammary tumors, which sug-
gests that additional factors other than differentiation must
play a role.
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The chemokine CXCL12 and its receptor CXCR4 are
known to function in leukocyte migration to inflammatory
sites.74 With regard to tumorigenesis, CXCR4 is often over-
expressed in human cancers, and CXCL12 may also play a
role in survival, proliferation or angiogenesis in the primary
tumor.75,76 Additionally, they are believed to play a role in
directing the migration of cancer cells to secondary meta-
static sites.77 Hsu et al.51 recently reported that TCDD treat-
ment reduced the expression of these factors in MCF-7 cells,
and postulated that this may contribute to the protective
effect of AhR activation in breast cancer. A subsequent
report by Hall et al. described similar suppression of
CXCR4 by TCDD in additional ERþ and ER breast can-
cer cell lines.67 In our studies, TCDD treatment caused a
transient increase in the expression of both molecules in the
mammary gland. The cause of this increase in the absence
of antigen challenge is unclear, although it could reflect an
enhanced inflammatory response that is commonly observed
in TCDD-treated animals.78–80 Regardless, this increase was
transient and did not persist at the time of carcinogen
administration. There was suggestive evidence that CXCR4
expression was diminished in tumors from the TCDD-
treated mice, which would be consistent with observations
by Hsu et al. and Hall et al. in the cultured tumor cells.
However, the decrease was not technically statistically sig-
nificant. Taken together our results do not provide strong
support for a link between delayed tumor formation and
changes in CXCL12 or CXCR4, although the potential for
these molecules to influence continued tumor growth or
metastasis warrants further exploration.
As discussed previously, Lamartiniere and coworkers have
demonstrated that developmental exposure to TCDD alters
gland development and also increases susceptibility to mam-
mary tumorigenesis.22,23 Thus, it is reasonable that the differ-
entiation state of cells in the mammary gland at the time of
AhR activation will influence susceptibility to neoplastic
transformation. Our original intention was to test whether
the AhR-mediated suppression of normal pregnancy-induced
mammary differentiation would likewise increase susceptibil-
ity to tumor development. However, our results did not sup-
port this hypothesis for glandular differentiation caused by
pregnancy. We did not find that altered glandular develop-
ment caused by TCDD influenced the development of
DMBA-induced tumors; tumor development was delayed by
TCDD treatment regardless of whether the animal was preg-
nant or not at the time of exposure.
In summary, our results show that AhR activation causes
a persistent change in mammary cells that delays tumor for-
mation, and add to the growing number of studies that have
demonstrated that AhR activation reduces mammary tumor
incidence or causes regression of existing tumors. In combina-
tion with other findings such as overexpression of AhR in
mammary tumors,62,63,68 effects of AhR activation on cell cycle
regulation and invasiveness of breast cancer cells,67,81 and the
discovery that a metabolite of tamoxifen activates AhR,82 this
report underscores the importance of understanding the role
of the receptor in breast cancer. We hypothesize that the bene-
ficial effect observed in our studies occurs via inhibiting tumor
promotion, specifically by slowing the growth of preneoplastic
lesions and initial tumors. This is promising because it pro-
vides an opportunity for biologic intervention in situations
where initiation has already occurred, and provides tantalizing
evidence to support continued exploration into the use of
SAhRMs in breast cancer treatment and prevention.
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